Yuan Yuan Ling

The healthspan of mice is enhanced by killing senescent cells using a transgenic suicide gene. Achieving the same using small molecules would have a tremendous impact on quality of life and the burden of age-related chronic diseases. Here, we describe the rationale for identification and validation of a new class of drugs termed senolytics, which selectively kill senescent cells. By transcript analysis, we discovered increased expression of pro-survival networks in senescent cells, consistent with their established resistance to apoptosis. Using siRNA to silence expression of key nodes of this network, including ephrins (EFNB1 or 3), PI3Kδ, p21, BCL-xL, or plasminogen-activated inhibitor-2, killed senescent cells, but not proliferating or quiescent, differentiated cells. Drugs targeting these same factors selectively killed senescent cells. Dasatinib eliminated senescent human fat cell progenitors, while quercetin was more effective against senescent human endothelial cells and mouse BM-MSCs. The combination of dasatinib and quercetin was effective in eliminating senescent MEFs. In vivo, this combination reduced senescent cell burden in chronologically aged, radiation-exposed, and progeroid Ercc1(-/Δ) mice. In old mice, cardiac function and carotid vascular reactivity were improved 5 days after a single dose. Following irradiation of one limb in mice, a single dose led to improved exercise capacity for at least 7 months following drug treatment. Periodic drug administration extended healthspan in Ercc1(-/∆) mice, delaying age-related symptoms and pathology, osteoporosis, and loss of intervertebral disk proteoglycans. These results demonstrate the feasibility of selectively ablating senescent cells and the efficacy of senolytics for alleviating symptoms of frailty and extending healthspan.

BACKGROUND: Senescence is a tumor suppressor mechanism activated in stressed cells to prevent replication of damaged DNA. Senescent cells have been demonstrated to play a causal role in driving aging and age-related diseases using genetic and pharmacologic approaches. We previously demonstrated that the combination of dasatinib and the flavonoid quercetin is a potent senolytic improving numerous age-related conditions including frailty, osteoporosis and cardiovascular disease. The goal of this study was to identify flavonoids with more potent senolytic activity. METHODS: -luciferase reporter and aged wild-type mice to determine the effects of fisetin on senescence markers, age-related histopathology, disease markers, health span and lifespan. Human adipose tissue explants were used to determine if results translated. FINDINGS: Of the 10 flavonoids tested, fisetin was the most potent senolytic. Acute or intermittent treatment of progeroid and old mice with fisetin reduced senescence markers in multiple tissues, consistent with a hit-and-run senolytic mechanism. Fisetin reduced senescence in a subset of cells in murine and human adipose tissue, demonstrating cell-type specificity. Administration of fisetin to wild-type mice late in life restored tissue homeostasis, reduced age-related pathology, and extended median and maximum lifespan. INTERPRETATION: The natural product fisetin has senotherapeutic activity in mice and in human tissues. Late life intervention was sufficient to yield a potent health benefit. These characteristics suggest the feasibility to translation to human clinical studies. FUND: NIH grants P01 AG043376 (PDR, LJN), U19 AG056278 (PDR, LJN, WLL), R24 AG047115 (WLL), R37 AG013925 (JLK), R21 AG047984 (JLK), P30 DK050456 (Adipocyte Subcore, JLK), a Glenn Foundation/American Federation for Aging Research (AFAR) BIG Award (JLK), Glenn/AFAR (LJN, CEB), the Ted Nash Long Life and Noaber Foundations (JLK), the Connor Group (JLK), Robert J. and Theresa W. Ryan (JLK), and a Minnesota Partnership Grant (AMAY-UMN#99)-P004610401-1 (JLK, EAA).

Abstract Aging is the main risk factor for many chronic degenerative diseases and cancer. Increased senescent cell burden in various tissues is a major contributor to aging and age-related diseases. Recently, a new class of drugs termed senolytics were demonstrated to extending healthspan, reducing frailty and improving stem cell function in multiple murine models of aging. To identify novel and more optimal senotherapeutic drugs and combinations, we established a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells. We used primary Ercc1 −/− murine embryonic fibroblasts with reduced DNA repair capacity, which senesce rapidly if grown at atmospheric oxygen. This platform was used to screen a small library of compounds that regulate autophagy, identifying two inhibitors of the HSP90 chaperone family as having significant senolytic activity in mouse and human cells. Treatment of Ercc1 −/∆ mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended healthspan, delayed the onset of several age-related symptoms and reduced p16 INK4a expression. These results demonstrate the utility of our screening platform to identify senotherapeutic agents as well as identified HSP90 inhibitors as a promising new class of senolytic drugs.

c-Jun N-terminal kinase 3α1 (JNK3α1) is a mitogen-activated protein kinase family member expressed primarily in the brain that phosphorylates protein transcription factors, including c-Jun and activating transcription factor-2 (ATF-2) upon activation by a variety of stress-based stimuli. In this study, we set out to design JNK3-selective inhibitors that had >1000-fold selectivity over p38, another closely related mitogen-activated protein kinase family member. To do this we employed traditional medicinal chemistry principles coupled with structure-based drug design. Inhibitors from the aminopyrazole class, such as SR-3576, were found to be very potent JNK3 inhibitors (IC50 = 7 nm) with >2800-fold selectivity over p38 (p38 IC50 > 20 μm) and had cell-based potency of ∼1 μm. In contrast, indazole-based inhibitors exemplified by SR-3737 were potent inhibitors of both JNK3 (IC50 = 12 nm) and p38 (IC50 = 3 nm). These selectivity differences between the indazole class and the aminopyrazole class came despite nearly identical binding (root mean square deviation = 0.33 Å) of these two compound classes to JNK3. The structural features within the compounds giving rise to the selectivity in the aminopyrazole class include the highly planar nature of the pyrazole, N-linked phenyl structures, which better occupied the smaller active site of JNK3 compared with the larger active site of p38. c-Jun N-terminal kinase 3α1 (JNK3α1) is a mitogen-activated protein kinase family member expressed primarily in the brain that phosphorylates protein transcription factors, including c-Jun and activating transcription factor-2 (ATF-2) upon activation by a variety of stress-based stimuli. In this study, we set out to design JNK3-selective inhibitors that had >1000-fold selectivity over p38, another closely related mitogen-activated protein kinase family member. To do this we employed traditional medicinal chemistry principles coupled with structure-based drug design. Inhibitors from the aminopyrazole class, such as SR-3576, were found to be very potent JNK3 inhibitors (IC50 = 7 nm) with >2800-fold selectivity over p38 (p38 IC50 > 20 μm) and had cell-based potency of ∼1 μm. In contrast, indazole-based inhibitors exemplified by SR-3737 were potent inhibitors of both JNK3 (IC50 = 12 nm) and p38 (IC50 = 3 nm). These selectivity differences between the indazole class and the aminopyrazole class came despite nearly identical binding (root mean square deviation = 0.33 Å) of these two compound classes to JNK3. The structural features within the compounds giving rise to the selectivity in the aminopyrazole class include the highly planar nature of the pyrazole, N-linked phenyl structures, which better occupied the smaller active site of JNK3 compared with the larger active site of p38. Because the initial reports on the discovery of p38 (1Lee J.C. Laydon J.T. McDonnell P.C. Gallagher T.F. Kumar S. Green D. McNulty D. Blumenthal M.J. Keys J.R. Landvatter S.W. Strickler J.E. McLaughlin M.M. Siemens I.R. Fisher S.M. Livi G.P. White J.R. Adams J.L. Young P.R. Nature. 1994; 372: 739-746Crossref PubMed Scopus (3135) Google Scholar) and c-Jun N-terminal kinase (JNK) 2The abbreviations used are: JNK, c-Jun N-terminal kinase; ATF-2, activating transcription factor-2; AMP-PCP, adenosine 5′-(β,γ-methylenetriphosphate); Bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; SAR, structure-activity relationship; r.m.s.d., root mean square deviation. 2The abbreviations used are: JNK, c-Jun N-terminal kinase; ATF-2, activating transcription factor-2; AMP-PCP, adenosine 5′-(β,γ-methylenetriphosphate); Bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; SAR, structure-activity relationship; r.m.s.d., root mean square deviation. (2Derijard B. Hibi M. Wu I.H. Barrett T. Su B. Deng T. Karin M. Davis R.J. Cell. 1994; 76: 1025-1037Abstract Full Text PDF PubMed Scopus (2955) Google Scholar, 3Hibi M. Lin A. Smeal T. Minden A. Karin M. Genes Dev. 1993; 7: 2135-2148Crossref PubMed Scopus (1709) Google Scholar, 4Kyriakis J.M. Banerjee P. Nikolakaki E. Dai T. Rubie E.A. Ahmad M.F. Avruch J. Woodgett J.R. Nature. 1994; 369: 156-160Crossref PubMed Scopus (2413) Google Scholar, 5Minden A. Lin A. Smeal T. Derijard B. Cobb M. Davis R. Karin M. Mol. Cell. Biol. 1994; 14: 6683-6688Crossref PubMed Scopus (436) Google Scholar, 6Sluss H.K. Barrett T. Derijard B. Davis R.J. Mol. Cell. Biol. 1994; 14: 8376-8384Crossref PubMed Scopus (445) Google Scholar) these mitogen-activated protein kinase family members have generated great interest as drug targets. p38 especially has garnered considerable interest, particularly for the treatment of rheumatoid arthritis and Crohn disease, and numerous compounds have entered clinical trials for these indications (7Dominguez C. Powers D.A. Tamayo N. Curr. Opin. Drug Discov. Dev. 2005; 8: 421-430PubMed Google Scholar, 8Haddad J.J. Curr. Opin. Investig. Drugs. 2001; 2: 1070-1076PubMed Google Scholar, 9Lee M.R. Dominguez C. Curr. Med. Chem. 2005; 12: 2979-2994Crossref PubMed Scopus (218) Google Scholar, 10Regan J. Breitfelder S. Cirillo P. Gilmore T. Graham A.G. Hickey E. Klaus B. Madwed J. Moriak M. Moss N. Pargellis C. Pav S. Proto A. Swinamer A. Tong L. Torcellini C. J. Med. Chem. 2002; 45: 2994-3008Crossref PubMed Scopus (358) Google Scholar, 11Schreiber S. Feagan B. D'Haens G. Colombel J.F. Geboes K. Yurcov M. Isakov V. Golovenko O. Bernstein C.N. Ludwig D. Winter T. Meier U. Yong C. Steffgen J. Clin. Gastroenterol. Hepatol. 2006; 4: 325-334Abstract Full Text Full Text PDF PubMed Scopus (162) Google Scholar). Because most of the p38 inhibitors are competitive versus ATP (12de Dios A. Shih C. Lopez de Uralde B. Sanchez C. del Prado M. Martin Cabrejas L.M. Pleite S. Blanco-Urgoiti J. Lorite M.J. Nevill Jr., C.R. Bonjouklian R. York J. Vieth M. Wang Y. Magnus N. Campbell R.M. Anderson B.D. McCann D.J. Giera D.D. Lee P.A. Schultz R.M. Li L.C. Johnson L.M. Wolos J.A. J. Med. Chem. 2005; 48: 2270-2273Crossref PubMed Scopus (58) Google Scholar, 13Goldstein D.M. Alfredson T. Bertrand J. Browner M.F. Clifford K. Dalrymple S.A. Dunn J. Freire-Moar J. Harris S. Labadie S.S. La Fargue J. Lapierre J.M. Larrabee S. Li F. Papp E. McWeeney D. Ramesha C. Roberts R. Rotstein D. San Pablo B. Sjogren E.B. So O.Y. Talamas F.X. Tao W. Trejo A. Villasenor A. Welch M. Welch T. Weller P. Whiteley P.E. Young K. Zipfel S. J. Med. Chem. 2006; 49: 1562-1575Crossref PubMed Scopus (62) Google Scholar, 14LoGrasso P.V. Frantz B. Rolando A.M. O'Keefe S.J. Hermes J.D. O'Neill E.A. Biochemistry. 1997; 36: 10422-10427Crossref PubMed Scopus (102) Google Scholar, 15Swahn B.M. Xue Y. Arzel E. Kallin E. Magnus A. Plobeck N. Viklund J. Bioorg. Med. Chem. Lett. 2006; 16: 1397-1401Crossref PubMed Scopus (51) Google Scholar, 16Young P.R. McLaughlin M.M. Kumar S. Kassis S. Doyle M.L. McNulty D. Gallagher T.F. Fisher S. McDonnell P.C. Carr S.A. Huddleston M.J. Seibel G. Porter T.G. Livi G.P. Adams J.L. Lee J.C. J. Biol. Chem. 1997; 272: 12116-12121Abstract Full Text Full Text PDF PubMed Scopus (537) Google Scholar, 17Zhao H. Serby M.D. Xin Z. Szczepankiewicz B.G. Liu M. Kosogof C. Liu B. Nelson L.T. Johnson E.F. Wang S. Pederson T. Gum R.J. Clampit J.E. Haasch D.L. Abad-Zapatero C. Fry E.H. Rondinone C. Trevillyan J.M. Sham H.L. Liu G. J. Med. Chem. 2006; 49: 4455-4458Crossref PubMed Scopus (69) Google and are in the to compounds that are a of that compounds be to clinical The that rise to p38 inhibitors from numerous structural classes has J.E. Liu L. G. S. Wang Z. J.R. E.A. O'Keefe S.J. O'Neill E.A. D.M. D.M. Bioorg. Lett. PubMed Scopus Google Scholar, J. A. Frantz B. O'Neill E.A. G. O'Keefe S.J. Li B. C. de S. A. B. N. Hermes J. P. Biochemistry. PubMed Scopus Google Scholar, K. S. V. M.J. P.R. Su Chem. Biol. 1997; 4: Full Text PDF PubMed Scopus Google Scholar) and is on differences the in p38 in of the and in the mitogen-activated protein kinase family compounds have that of this in p38, compared with and the of the compounds have and which to p38 selectivity D.A. S.M. A. L. K. Frantz B. S.J. M. Lin J. S. O'Neill E.A. M. J. Rolando A. Y. D.M. O'Keefe S.J. J. Med. Chem. PubMed Scopus Google Scholar). In to p38, have reports for and the clinical of inhibitors that of p38. the of highly inhibitors that have to clinical numerous reports have to that compounds from structural classes and selectivity for over p38 A. Lin A. Smeal T. Derijard B. Cobb M. Davis R. Karin M. Mol. Cell. Biol. 1994; 14: 6683-6688Crossref PubMed Scopus (436) Google Scholar, 15Swahn B.M. Xue Y. Arzel E. Kallin E. Magnus A. Plobeck N. Viklund J. Bioorg. Med. Chem. Lett. 2006; 16: 1397-1401Crossref PubMed Scopus (51) Google Scholar, 17Zhao H. Serby M.D. Xin Z. Szczepankiewicz B.G. Liu M. Kosogof C. Liu B. Nelson L.T. Johnson E.F. Wang S. Pederson T. Gum R.J. Clampit J.E. Haasch D.L. Abad-Zapatero C. Fry E.H. Rondinone C. Trevillyan J.M. Sham H.L. Liu G. J. Med. Chem. 2006; 49: 4455-4458Crossref PubMed Scopus (69) Google Scholar, R.M. M.J. J.A. M. Dunn S. J.R. M. P. J.L. S.A. G. Wang R. Bioorg. Med. Chem. Lett. PubMed Scopus Google Scholar, P. V. S. Y. M. C. D. Cirillo R. D. S. A. C. P.A. J. Med. Chem. 2005; 48: PubMed Scopus Google Scholar, B.G. Kosogof C. Nelson L.T. Liu G. Liu B. H. Serby M.D. Xin Z. Liu M. Gum R.J. Haasch D.L. Wang S. Clampit J.E. Johnson E.F. C. S.A. K. Abad-Zapatero C. Fry E.H. Sham H.L. Rondinone Trevillyan J.M. J. Med. Chem. 2006; 49: PubMed Scopus Google Scholar). The of p38 (7Dominguez C. Powers D.A. Tamayo N. Curr. Opin. Drug Discov. Dev. 2005; 8: 421-430PubMed Google Scholar) this selectivity in in a class of indazole JNK3 inhibitors that were p38 with the of compound that a selectivity for JNK3 over p38 B.M. F. Kallin E. J. T. Viklund J. P. Xue Y. L. Bioorg. Med. Chem. Lett. 2005; PubMed Scopus Google Scholar). The on inhibitors came protein which as drug for T. L. A. M. J. C. Med. PubMed Scopus Google S. M. P. Davis R.J. S. P. U. S. A. PubMed Scopus Google Scholar, T. Weller M. A. U. S. A. 2001; PubMed Scopus Google and H. Y. T. D. M. Y. H. Y. M. Med. PubMed Scopus Google Scholar). for and have J.E. Liu L. G. S. Wang Z. J.R. E.A. O'Keefe S.J. O'Neill E.A. D.M. D.M. Bioorg. Lett. PubMed Scopus Google Scholar, D. O'Keefe S.J. G. Biol. PubMed Scopus Google Scholar, Lee Lee S. J.M. Lee T.G. J. PubMed Scopus Google Scholar, G. J. P.V. Chem. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar, L. Pav S. White D.M. S. M.L. Pargellis Biol. 1997; 4: PubMed Scopus Google Scholar, Y. T. J.T. W. P.R. Su Full Text Full Text PDF PubMed Scopus Google Scholar). In Tong L. Pav S. White D.M. S. M.L. Pargellis Biol. 1997; 4: PubMed Scopus Google Scholar) the of the with the of the of the with the of a within the ATP binding of p38. In J. A. Frantz B. O'Neill E.A. G. O'Keefe S.J. Li B. C. de S. A. B. N. Hermes J. P. Biochemistry. PubMed Scopus Google Scholar) that p38 inhibitors be to 3 μm) on p38 the in p38 to the found in the K. S. V. M.J. P.R. Su Chem. Biol. 1997; 4: Full Text PDF PubMed Scopus Google Scholar) this to be for p38 selectivity over In G. J. P.V. Chem. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar) the of which that the of JNK3 a that the planar the smaller binding of JNK3 this compound highly over p38, which has a larger ATP binding the a structural for JNK3 G. J. P.V. Chem. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar). the for as a drug and the of a structural classes of compounds that have B.M. Xue Y. Arzel E. Kallin E. Magnus A. Plobeck N. Viklund J. Bioorg. Med. Chem. Lett. 2006; 16: 1397-1401Crossref PubMed Scopus (51) Google Scholar, 17Zhao H. Serby M.D. Xin Z. Szczepankiewicz B.G. Liu M. Kosogof C. Liu B. Nelson L.T. Johnson E.F. Wang S. Pederson T. Gum R.J. Clampit J.E. Haasch D.L. Abad-Zapatero C. Fry E.H. Rondinone C. Trevillyan J.M. Sham H.L. Liu G. J. Med. Chem. 2006; 49: 4455-4458Crossref PubMed Scopus (69) Google Scholar, R.M. M.J. J.A. M. Dunn S. J.R. M. P. J.L. S.A. G. Wang R. Bioorg. Med. Chem. Lett. PubMed Scopus Google Scholar, P. V. S. Y. M. C. D. Cirillo R. D. S. A. C. P.A. J. Med. Chem. 2005; 48: PubMed Scopus Google Scholar, B.G. Kosogof C. Nelson L.T. Liu G. Liu B. H. Serby M.D. Xin Z. Liu M. Gum R.J. Haasch D.L. Wang S. Clampit J.E. Johnson E.F. C. S.A. K. Abad-Zapatero C. Fry E.H. Sham H.L. Rondinone Trevillyan J.M. J. Med. Chem. 2006; 49: PubMed Scopus Google we set out to selectivity over p38 be with indazole class of compounds and were to selectivity for JNK3 over p38. to aminopyrazole class of compounds that compounds with >2800-fold selectivity for JNK3 over p38. To do this we traditional structure-activity by and cell-based with structure-based drug design. The of this despite nearly identical binding 0.33 Å) and for the indazole-based JNK3 IC50 = 12 nm) compared with the JNK3 IC50 = the two classes of compounds had binding to p38 (IC50 = and the p38 potency of and selectivity for to the highly planar nature of the pyrazole, N-linked phenyl and better the smaller active site of JNK3 compared with the larger active site of p38. and of expressed in the of a in with to of the and with and The to = and the to and with for The with and with for a and by The from of in 20 of and and in on The by for with of and The in and and the the the with of A. The with a of and and were and by JNK3 were with and the The with of and with a of B. were and by JNK3 were and a and JNK3 were by and to be were and to and of from the by from as of the of ATF-2, to were the and and were the to the and of with a the expressed in in with and = to the and the with and for a The and with and to a The with of and with protein a The with of and with the were by and to be on were in for with a in the of kinase for the in the of the from and of compounds out in from to the kinase by of of with from The nm) and were from The a The from were and as the mean IC50 were by the to the for a p38 were to the JNK3 with the that the ATP = and p38 = were in a in a and and in by a with were with of in for 3 in treatment the and the were in The and the were in and inhibitors were to the of the and The c-Jun and the coupled were from of and on a of IC50 were a and a for of the inhibitors of of of and of SR-3737 and the for the of SR-3737 be found in the with the indazole with Anderson D. L. A. J. Chem. PubMed Scopus Google Scholar, J. Scopus Google Scholar). of the by of the H. J. J. Chem. PubMed Scopus Google Scholar, J. Chem. Scopus Google Scholar) the and the The compounds in the were in a for be found in the were the in to the Z. B. T. D. M. Nelson J. S. M. J. J. R. T. J. Med. Chem. 2005; 48: PubMed Scopus Google Scholar). with by and the of the to the by with the the were by and were as by of JNK3 with AMP-PCP, and to and on for JNK3 a with the within in Bis-Tris, and a protein in Bis-Tris, and were within and by of and SR-3737 were in and the a the compounds were the over were in on and for and of were for were on M.D. A.M. J. 2002; PubMed Scopus Google Scholar). were and to the Z. W. 1997; PubMed Scopus Google Scholar). and out R.J. J.C. Biol. 2002; PubMed Scopus Google Scholar) P. K. Biol. PubMed Scopus Google Scholar) for and The used for and A. Wang J. PubMed Scopus Google Scholar). for SR-3737 and were generated the D.M. Biol. PubMed Scopus Google Scholar) and The were the and for SR-3737 and for and the IC50 for the indazole-based inhibitors of and p38. The compound from this class, a potent JNK3 and p38 potency for p38 over JNK3. the had selectivity for JNK3 over p38, and this for we were to a structure-activity for the indazole that JNK3 potency and selectivity over p38, we the selectivity of aminopyrazole The aminopyrazole inhibitors in are in to the indazole-based inhibitors of and The are the for the and for the of the compounds in selectivity for JNK3 over p38. is a for the we p38 μm. in a 7 JNK3 >2800-fold selectivity over p38 and on the had on JNK3 potency with and JNK3 potency by the of the potent and selectivity for JNK3 over for aminopyrazole inhibitors for JNK3 and for p38 and deviation for the >2800-fold selectivity of compounds such as for JNK3 over p38, we the cell-based of these compounds in In this compounds IC50 of for the of c-Jun The with in the of to with = for aminopyrazole inhibitors = for deviation of of and JNK3 were and and to of for SR-3737 and for with found in In the between the and were in as the be to of were as and to Because by in potency from SR-3576, and the the generated SR-3576, we a structural for the the of SR-3737 and in JNK3 The between the two is 0.33 The between the of and of in JNK3 and the between the indazole of SR-3737 and of in JNK3 are as the between the of in JNK3 and the of SR-3737 is as a active site are including the and The between on the and phenyl in JNK3 the between this in SR-3737 and of JNK3 The of both compounds the of the of the to to the nature of the compound the the the to be in the to the that in were and in the have in JNK3 B.M. Xue Y. Arzel E. Kallin E. Magnus A. Plobeck N. Viklund J. Bioorg. Med. Chem. Lett. 2006; 16: 1397-1401Crossref PubMed Scopus (51) Google Scholar, R.M. M.J. J.A. M. Dunn S. J.R. M. P. J.L. S.A. G. Wang R. Bioorg. Med. Chem. Lett. PubMed Scopus Google Scholar, B.M. F. Kallin E. J. T. Viklund J. P. Xue Y. L. Bioorg. Med. Chem. Lett. 2005; PubMed Scopus Google Scholar, G. J. P.V. Chem. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar, Y. T. J.T. W. P.R. Su Full Text Full Text PDF PubMed Scopus Google Scholar, A.M. C. J. G. Green J. M.R. M. F. G. J. J. Med. Chem. PubMed Scopus (102) Google and = = = = = = of = and = a of the that are from in are for the and = a of the that are from in are for the = and = a of the that are from in are for the in a SR-3737 and in the ATP of JNK3 in a very and compounds of the the with the of and a with the of The phenyl in both compounds very in of and with the deviation in the the with by a between the indazole N-linked phenyl and the indazole of SR-3737 compared with the with the and the N-linked phenyl of The structural differences between the two were the of the ATP binding and of JNK3 In to the binding of SR-3737 to p38, we the for p38 = SR-3737 p38 and upon the of a with p38 from J.E. Liu L. G. S. Wang Z. J.R. E.A. O'Keefe S.J. O'Neill E.A. D.M. D.M. Bioorg. Lett. PubMed Scopus Google Scholar). is a 3 of p38. The for of the structural features between the two the of compound with the in SR-3737 the indazole of SR-3737 with the of compound the N-linked phenyl of SR-3737 with the N-linked of compound The phenyl of SR-3737 to binding to p38 compared with compound that IC50 were the 3 for the p38 protein are To better the structural and differences between JNK3 and p38 with the compounds we p38, and the compounds the protein of JNK3 p38 with SR-3737 and compound from J.E. Liu L. G. S. Wang Z. J.R. E.A. O'Keefe S.J. O'Neill E.A. D.M. D.M. Bioorg. Lett. PubMed Scopus Google Scholar). the of the binding with the of the binding with and compound from J.E. Liu L. G. S. Wang Z. J.R. E.A. O'Keefe S.J. O'Neill E.A. D.M. D.M. Bioorg. Lett. PubMed Scopus Google Scholar). the of the binding with and compound from J.E. Liu L. G. S. Wang Z. J.R. E.A. O'Keefe S.J. O'Neill E.A. D.M. D.M. Bioorg. Lett. PubMed Scopus Google Scholar). The of this to design inhibitors that were over p38 and to the structure-activity were within the inhibitors that this To do this we employed traditional medicinal chemistry principles and this with structure-based drug design. drug design has in the of a of such as the B.M. J.J. C.N. 1994; PubMed Scopus (62) Google and including Z. Li Y. E. D.L. C. J.A. L.C. J. Biol. Chem. 1994; Full Text PDF PubMed Google Scholar, B.D. J.A. E.A. J.C. Lin D. Anderson J.R. J. Med. Chem. 1994; PubMed Scopus Google Scholar) and P.A. Chem. Biol. 2: Full Text PDF PubMed Scopus Google Scholar, S.W. J.F. J.E. K. J.A. D.A. Su J. Med. Chem. 1997; PubMed Scopus Google Scholar). in the of for the kinase by the that to the of the T. W. P. B. J. PubMed Scopus Google Scholar). numerous of p38 with inhibitors have J.E. Liu L. G. S. Wang Z. J.R. E.A. O'Keefe S.J. O'Neill E.A. D.M. D.M. Bioorg. Lett. PubMed Scopus Google Scholar, D. O'Keefe S.J. G. Biol. PubMed Scopus Google Scholar, L. Pav S. White D.M. S. M.L. Pargellis Biol. 1997; 4: PubMed Scopus Google the for p38 selectivity J.E. Liu L. G. S. Wang Z. J.R. E.A. O'Keefe S.J. O'Neill E.A. D.M. D.M. Bioorg. Lett. PubMed Scopus Google Scholar, D.A. S.M. A. L. K. Frantz B. S.J. M. Lin J. S. O'Neill E.A. M. J. Rolando A. Y. D.M. O'Keefe S.J. J. Med. Chem. PubMed Scopus Google Scholar) and the for this selectivity on J. A. Frantz B. O'Neill E.A. G. O'Keefe S.J. Li B. C. de S. A. B. N. Hermes J. P. Biochemistry. PubMed Scopus Google Scholar, K. S. V. M.J. P.R. Su Chem. Biol. 1997; 4: Full Text PDF PubMed Scopus Google Scholar) had to the of these the to the and had The set of be for In this we had to on traditional medicinal chemistry principles to compounds on from the structural are on of the to of the in and p38 these had on the that had on selectivity came from on the phenyl to the indazole be the of the for is in the that the binding in p38 is larger and that in JNK3 J.E. Liu L. G. S. Wang Z. J.R. E.A. O'Keefe S.J. O'Neill E.A. D.M. D.M. Bioorg. Lett. PubMed Scopus Google Scholar, G. J. P.V. Chem. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar, L. Pav S. White D.M. S. M.L. Pargellis Biol. 1997; 4: PubMed Scopus Google Scholar, Y. T. J.T. W. P.R. Su Full Text Full Text PDF PubMed Scopus Google Scholar). this be the for of the for the in and of the selectivity for JNK3 over p38 to the of the in the the occupied by these compounds the larger p38 active compound that selectivity for JNK3 over p38 which had a that and have within the active that the in p38 the of the N-linked phenyl of the from in JNK3. is in p38. The of this that as a p38 were to the smaller this on the has this and with the J. A. Frantz B. O'Neill E.A. G. O'Keefe S.J. Li B. C. de S. A. B. N. Hermes J. P. Biochemistry. PubMed Scopus Google Scholar) the in p38 is to the larger found in inhibitors of p38 potent p38. is that the larger in JNK3 coupled with the for JNK3 with of p38 to the smaller for used to the in the indazole the indazole phenyl to a of To the of the indazole in this and of we used a to the and that the nature of the a the and this a in JNK3 potency a in p38 to for selectivity p38 with nearly that the indazole phenyl had were with the N-linked phenyl in this the pyrazole, N-linked phenyl as as the for binding the smaller JNK3 active the the of in JNK3 a deviation from between the and N-linked phenyl the a the phenyl as In this the and great as to the as by SR-3737 have selectivity for JNK3 the as by is that of the for JNK3 and p38 with compounds from the of the The of the differences in between the active and of a JNK3 be to these despite the that p38 and JNK3 have very in the p38 and active and these active to the of active be to these for and the and a to selectivity for JNK3 versus the of SR-3737 and that both structural in within JNK3. In the the and the in the that the selectivity The to the in both that the selectivity is with in JNK3 versus the binding to be for JNK3 and the is in with that the of the and binding to the in selectivity R.M. M.J. J.A. M. Dunn S. J.R. M. P. J.L. S.A. G. Wang R. Bioorg. Med. Chem. Lett. PubMed Scopus Google Scholar, B.M. F. Kallin E. J. T. Viklund J. P. Xue Y. L. Bioorg. Med. Chem. Lett. 2005; PubMed Scopus Google Scholar, G. J. P.V. Chem. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar, Y. T. J.T. W. P.R. Su Full Text Full Text PDF PubMed Scopus Google Scholar). for of this cell-based is to the compounds we were and to the cell-based potency a which the cell-based IC50 for in the is of in the of this is from and are from is this are that have for JNK3 in this the in for is that most of the in this be from and most of the in the cell-based IC50 within to compared with that for the These that the are inhibitors and that the potency is in this a cell-based for that JNK3 in the and were factors, the IC50 in for JNK3 be for compounds such as and In a of we have to a class of aminopyrazole inhibitors that are very potent JNK3 inhibitors with >2800-fold selectivity over p38 and have cell-based within to of the The structural features within the compounds giving rise to the selectivity in the aminopyrazole class include the highly planar nature of the pyrazole, N-linked phenyl structures, which better the smaller active site of JNK3 compared with the larger active site of p38. selectivity for the found for JNK3 over with and with of p38 with these structural features that the design of highly are to for in the with

There are currently no drugs to treat neurodegeneration in Parkinson's disease (PD) and all existing medications only treat symptoms, lose efficacy over time, and produce untoward side effects. In the current work, we report the first highly selective, orally bioavailable, c-jun-N-terminal kinase (JNK) inhibitor for protection of dopaminergic neurons in vitro and in vivo. At 300 nM this compound showed statistically significant protection of primary dopaminergic neurons exposed to 1-methyl-4-phenylpyridinium (MPP(+)), had pharmacokinetic properties in rodents consistent with twice daily (b.i.d.) dosing, and was orally efficacious at 30 mg/kg in a mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease. Moreover, a dose-dependent target modulation of c-jun phosphorylation served as a biomarker for demonstrating on-target inhibition of JNK as the mechanism of action for this compound. Collectively these results suggest that this JNK inhibitor could be a promising therapeutic neuroprotective agent in the treatment of Parkinson's disease.